NASDAQ · ANAB
Healthcare · Biotechnology
$47.97
Up+$1.52 (+3.27%)
Updated Nov 10, 2026, 8:12 AM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ANAB
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 9, 2026
ANAB closed at $47.97 after 21 trading sessions, up 4.19% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 9, 2026 | $47.03 | $48.96 | $46.19 | $47.97 | 323.84K |
| Nov 6, 2026 | $45.85 | $46.6294 | $45.01 | $46.45 | 287.79K |
| Nov 5, 2026 | $47.51 | $47.74 | $45.47 | $45.58 | 380.83K |
| Nov 4, 2026 | $49.00 | $49.00 | $45.81 | $47.51 | 528.26K |
| Nov 3, 2026 | $47.36 | $48.3475 | $47.36 | $47.73 | 304.86K |
| Nov 2, 2026 | $48.33 | $48.37 | $46.90 | $46.91 | 281.49K |
| Oct 30, 2026 | $48.68 | $48.97 | $47.885 | $48.28 | 293.62K |
| Oct 29, 2026 | $50.85 | $51.22 | $48.33 | $48.64 | 414.38K |
| Oct 28, 2026 | $49.59 | $50.55 | $49.00 | $50.50 | 309.83K |
| Oct 27, 2026 | $49.24 | $50.02 | $48.695 | $49.63 | 349.58K |
| Oct 26, 2026 | $48.97 | $49.62 | $47.98 | $48.77 | 417.2K |
| Oct 23, 2026 | $48.19 | $48.885 | $47.05 | $48.73 | 468.21K |
| Oct 22, 2026 | $47.65 | $48.51 | $46.83 | $48.10 | 254.92K |
| Oct 21, 2026 | $45.48 | $48.475 | $45.48 | $47.94 | 664.46K |
| Oct 20, 2026 | $49.57 | $51.855 | $44.02 | $45.43 | 1.21M |
| Oct 19, 2026 | $47.33 | $49.88 | $47.33 | $49.24 | 468.35K |
| Oct 16, 2026 | $48.56 | $48.56 | $46.46 | $46.61 | 413.64K |
| Oct 15, 2026 | $47.43 | $48.83 | $46.93 | $48.71 | 416.3K |
| Oct 14, 2026 | $45.25 | $47.235 | $45.00 | $46.67 | 494.17K |
| Oct 13, 2026 | $45.53 | $46.125 | $45.155 | $45.59 | 416.54K |
| Oct 12, 2026 | $46.16 | $46.78 | $45.985 | $46.04 | 371.66K |
The latest Smart Investors Daily articles mentioning ANAB.
Company
Market Activity
Research & News
ANAB research
Company profile and research snapshot.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 30, 2026 | JP Morgan | Overweight | — |
| Sep 24, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 23, 2026 | Leerink Partners | Outperform | — |
| Aug 25, 2026 | TD Cowen | Buy | — |
| Aug 24, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 31, 2026
Is ANAB a good stock to buy? We came across a bullish thesis on AnaptysBio, Inc. on TripleS Special Situations’s Substack. Since the thesis was published on June 15th, ANAB shares have pulled back as uncertainty over its GSK dispute and scrutiny of earnings boosted by a one-time tax benefit weighed on sentiment, creating a near-term hurdle […]
Yahoo · Oct 30, 2026
GSK’s surprise early FDA approval for Jemperli in certain MSI-H and dMMR locally advanced rectal cancers has pushed AnaptysBio (ANAB) into focus, given its role in discovering and out licensing the antibody. The fresh Jemperli approval has arrived after a mixed spell for AnaptysBio’s ticker, with the US$48.64 share price slipping over the past month and quarter while still showing an 8.21% year to date share price gain and a very large 3 year total shareholder return. Scan 36 healthcare AI...
Yahoo · Oct 28, 2026
Arcutis Biotherapeutics (ARQT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Yahoo · Oct 27, 2026
AnaptysBio (ANAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ANAB.
